论文部分内容阅读
进行开放性自身对照临床试验，验证添加拉莫三嗪治疗顽固性癫痫６３例的疗效和安全性。以治疗前３个月的发作频度为基础，治疗后观察３～１５个月。未服丙戊酸钠的成人平均维持量为２８９ｍｇ／ｄ；已服者为１４２ｍｇ／ｄ。癫痫全部发作类型的平均发作频度在治疗１２周时比治疗前降低３１％，发作频度减少≥５０％者占４１％，发作消失者占１４％。全身强直－阵挛型和全面性发作者疗效最佳，发作频度减少≥５０％者，在１２周时分别达６１％和６０％，平均发作频度分别减少５９％和３６％。治疗４～１５个月者５１例，疗效和近期相仿。Ｌｅｎｎｏｘ－Ｇａｓｔａｕｔ综合征的５例患者治疗１２周后，３例发作减少≥９６％。脑电图高度和中度不正常患者的比例，由治疗前的５０％，下降为１７％。拉莫三嗪副作用小，皮疹为主要表现，停药后消失。
To carry out open self-controlled clinical trials to validate the efficacy and safety of adding lamotrigine in 63 patients with intractable epilepsy. Based on the frequency of seizures in the first 3 months of treatment, the patients were observed for 3 to 15 months after treatment. Adult underage sodium valproate was maintained at an average of 289 mg / day and 142 mg / day. The average seizure frequency of all episodes of epilepsy decreased by 31% at 12 weeks of treatment, by 41% by 50% or more, and by 14% by episodes of episodes. Patients with generalized tonic-clonic and full-blown episodes had the best response with a 50% reduction in seizure frequency, 61% and 60% at 12 weeks, and a mean reduction of 59% and 36%, respectively. Treatment of 4 to 15 months in 51 cases, the effect and the recent similar. Five patients with Lennox-Gastaut syndrome had a reduction of ≥96% in 3 episodes after 12 weeks of treatment. The proportion of patients with high and moderate EEG abnormalities decreased from 50% before treatment to 17%. Little side effects of lamotrigine, rash as the main performance, disappeared after stopping.